SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Durbin Sean

(Last) (First) (Middle)
C/O LINDE PLC
FORGE, 43 CHURCH STREET W

(Street)
WOKING SURREY X0 GU216HT

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LINDE PLC [ LIN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive VP, EMEA
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 03/03/2023 M 5,945 A $118.71 16,377 D
Ordinary Shares(1) 03/03/2023 F 3,885 D $360.1 12,492 D
Ordinary Shares(1) 03/03/2023 S 2,060 D $360.04 10,432 D
Ordinary Shares(1) 03/03/2023 S 2,000 D $360.295 8,432 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(1) (2) (2) (7) Ordinary Shares 1,430 1,430 D
Restricted Stock Units(1) (3) (3) (8) Ordinary Shares 1,810 1,810 D
Restricted Stock Units(1) (4) (4) (9) Ordinary Shares 580 580 D
Stock Options (right to buy)(1) $270.99 03/07/2023(5) 03/07/2032 Ordinary Shares 12,395 12,395 D
Stock Options (right to buy)(1) $253.68 03/08/2022(6) 03/08/2031 Ordinary Shares 19,070 19,070 D
Stock Options (right to buy)(1) $173.13 03/09/2021(7) 03/09/2030 Ordinary Shares 7,045 7,045 D
Stock Options (right to buy)(1) $176.63 03/20/2020(8) 03/20/2029 Ordinary Shares 7,795 7,795 D
Stock Options (right to buy)(1) $154 02/27/2019(9) 02/27/2028 Ordinary Shares 16,170 16,170 D
Stock Options (right to buy)(1) $118.71 03/03/2023 M 5,945 02/28/2018(10) 02/28/2027 Ordinary Shares 5,945 $0 0 D
Deferred Stock Units(1) (11) (12) (12) Ordinary Shares 239.236 239.236 D
Explanation of Responses:
1. On March 1, 2023, Linde plc (formerly Rounderway plc), an Irish public limited company ("New Linde"), became the successor of Linde plc, an Irish public limited company ("Old Linde"), pursuant to a scheme of arrangement and merger under Irish law. Pursuant to the scheme of arrangement, all outstanding ordinary shares of Old Linde were exchanged, on a one-for-one basis, for ordinary shares of New Linde, and Old Linde subsequently merged into New Linde and ceased to exist. The transaction did not alter the relative interests of security holders.
2. Restricted Stock Units that will vest in full and payout on or about March 7, 2025 in Linde plc Ordinary Shares on a one-for-one basis.
3. Restricted Stock Units that will vest in full and payout on or about March 8, 2024 in Linde plc Ordinary Shares on a one-for-one basis.
4. Restricted Stock Units that will vest in full and payout on or about March 9, 2023 in Linde plc Ordinary Shares on a one-for-one basis.
5. This option vests over three years in three consecutive equal annual installments beginning on March 7, 2023.
6. This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022.
7. This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.
8. This option vests over three years in three consecutive equal annual installments beginning on March 20,2020.
9. This option vests over three years in three consecutive equal annual installments beginning on February 27, 2019.
10. This option vests over three years in three consecutive equal annual installments beginning on February 28, 2018.
11. Conversion to Linde plc Ordinary Shares is on a one-to-one basis.
12. Deferred stock units acquired under the Linde Compensation Deferral Plan as amended ("Plan"). The deferred stock units will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Plan.
Anthony M. Pepper, Attorney-in-fact 03/07/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.